{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:15:59Z","timestamp":1794651359439,"version":"4.9.1"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":269,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.atherosclerosis.2022.04.004","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T20:46:22Z","timestamp":1653079582000},"page":"101-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"special_numbering":"C","title":["Lipoprotein(a): An underestimated inflammatory mastermind"],"prefix":"10.1016","volume":"349","author":[{"given":"Kim E.","family":"Dzobo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Kraaijenhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S.G.","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick S.","family":"Nurmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9983-6614","authenticated-orcid":false,"given":"Jeffrey","family":"Kroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.04.004_bib1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.04.004_bib2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.004_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.03.003","article-title":"The dedicated \u201cLp(a) clinic\u201d: a concept whose time has arrived?","volume":"300","author":"Tsimikas","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.004_bib4","article-title":"Finding very high lipoprotein(a): the need for routine assessment","author":"Nurmohamed","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2022.04.004_bib5","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1001\/jamacardio.2018.3798","article-title":"Association of mild to moderate aortic valve stenosis progression with higher lipoprotein(a) and oxidized phospholipid levels: secondary analysis of a randomized clinical trial","volume":"3","author":"Capoulade","year":"2018","journal-title":"JAMA Cardiol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.04.004_bib6","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1194\/jlr.R083626","article-title":"The role of lipoprotein (a) in chronic kidney disease: thematic review series: lipoprotein (a): coming of age at last","volume":"59","author":"Hopewell","year":"2018","journal-title":"J. Lipid Res."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2022.04.004_bib7","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on Lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"Van Der Valk","year":"2016","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.04.004_bib8","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jacc.2015.05.066","article-title":"Calcification in aortic stenosis: the skeleton key","volume":"66","author":"Pawade","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"13","key":"10.1016\/j.atherosclerosis.2022.04.004_bib9","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials","volume":"63","author":"Raal","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"33","key":"10.1016\/j.atherosclerosis.2022.04.004_bib10","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1093\/eurheartj\/ehy862","article-title":"Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin\/kexin type 9 antibody treatment","volume":"40","author":"Stiekema","year":"2019","journal-title":"Eur. Heart J."},{"issue":"10057","key":"10.1016\/j.atherosclerosis.2022.04.004_bib11","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2022.04.004_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaa171","article-title":"Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a)","author":"Stiekema","year":"2020","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2022.04.004_bib13","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1161\/01.CIR.96.8.2514","article-title":"Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells","volume":"96","author":"Poon","year":"1997","journal-title":"Circulation"},{"issue":"1\u20132","key":"10.1016\/j.atherosclerosis.2022.04.004_bib14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0021-9150(95)05790-0","article-title":"Oxidized lipoprotein (a) induces cell adhesion molecule Mac-1 (CD 11b) and enhances adhesion of the monocytic cell line U937 to cultured endothelial cells","volume":"123","author":"Ragab","year":"1996","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.04.004_bib15","first-page":"559","article-title":"Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin","volume":"20","author":"Sotiriou","year":"2006","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.04.004_bib16","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood.V90.5.2027","article-title":"Lipoprotein(a) is a potent chemoattractant for human peripheral monocytes","volume":"90","author":"Syrovets","year":"1997","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.atherosclerosis.2022.04.004_bib17","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.1111\/j.1742-4658.2011.08237.x","article-title":"The ins and outs of pertussis toxin","volume":"278","author":"Locht","year":"2011","journal-title":"FEBS J."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.04.004_bib18","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.pharmthera.2009.02.009","article-title":"Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics","volume":"122","author":"Tsai","year":"2009","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.04.004_bib19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1161\/CIRCRESAHA.110.223875","article-title":"Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity","volume":"108","author":"Miller","year":"2011","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.04.004_bib20","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.coph.2013.02.005","article-title":"Oxidation-specific epitopes and immunological responses: translational biotheranostic implications for atherosclerosis","volume":"13","author":"Leibundgut","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2022.04.004_bib21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijcard.2020.05.008","article-title":"Short-term regulation of hematopoiesis by lipoprotein(a) results in the production of pro-inflammatory monocytes","volume":"315","author":"Schnitzler","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.004_bib22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.atherosclerosis.2022.04.001","article-title":"Oxidized phospholipid modification of lipoprotein(a): epidemiology, biochemistry and pathophysiology","volume":"349","author":"Koschinsky","year":"2022","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2022.04.004_bib23","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1161\/CIRCRESAHA.119.316206","article-title":"Atherogenic lipoprotein(a) increases vascular glycolysis, thereby facilitating inflammation and leukocyte extravasation","volume":"126","author":"Schnitzler","year":"2020","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.04.004_bib24","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1399-0004.1997.tb04348.x","article-title":"Apolipoprotein(a) is a human vascular endothelial cell agonist: studies on the induction in endothelial cells of monocyte chemotactic factor activity","volume":"52","author":"Poon","year":"1997","journal-title":"Clin. Genet."},{"issue":"15","key":"10.1016\/j.atherosclerosis.2022.04.004_bib25","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1096\/fasebj.12.15.1765","article-title":"Expression of adhesion molecules by Lp(a): a potential novel mechanism for its atherogenicity","volume":"12","author":"Allen","year":"1998","journal-title":"Faseb. J."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2022.04.004_bib26","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/01.CIR.97.8.721","article-title":"Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells","volume":"97","author":"Takami","year":"1998","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2022.04.004_bib27","doi-asserted-by":"crossref","first-page":"6526","DOI":"10.1074\/jbc.M309705200","article-title":"The apolipoprotein(a) component of lipoprotein(a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells","volume":"279","author":"Pellegrino","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.04.004_bib28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1161\/ATVBAHA.107.158014","article-title":"VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation","volume":"28","author":"Vestweber","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.04.004_bib29","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1091\/mbc.e12-08-0637","article-title":"Apolipoprotein(a) stimulates nuclear translocation of \u03b2catenin: a novel pathogenic mechanism for lipoprotein(a)","volume":"24","author":"Cho","year":"2013","journal-title":"Mol. Biol. Cell"},{"issue":"45","key":"10.1016\/j.atherosclerosis.2022.04.004_bib30","doi-asserted-by":"crossref","first-page":"30503","DOI":"10.1074\/jbc.M802648200","article-title":"Apolipoprotein(a), through its strong lysine-binding site in KIV 10, mediates increased endothelial cell contraction and permeability via a Rho\/Rho kinase\/MYPT1-dependent pathway","volume":"283","author":"Cho","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.04.004_bib31","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1046\/j.1523-1755.1999.00351.x","article-title":"Lp(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: role of oxidative stress","volume":"55","author":"Galle","year":"1999","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.04.004_bib32","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s11745-013-3795-1","article-title":"Oxidized lipoprotein(a) increases endothelial cell monolayer permeability via ROS generation","volume":"48","author":"Wei","year":"2013","journal-title":"Lipids"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.04.004_bib33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.atherosclerosis.2015.09.020","article-title":"Ox-Lp(a) transiently induces HUVEC autophagy via an ROS-dependent PAPR-1-LKB1-AMPK-mTOR pathway","volume":"243","author":"Li","year":"2015","journal-title":"Atherosclerosis"},{"issue":"1\u20132","key":"10.1016\/j.atherosclerosis.2022.04.004_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cell.2018.09.048","article-title":"Biological functions of autophagy genes: a disease perspective","volume":"176","author":"Levine","year":"2019","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.04.004_bib35","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1161\/ATVBAHA.114.304840","article-title":"ATG16L1 expression in carotid atherosclerotic plaques is associated with plaque vulnerability","volume":"35","author":"Magn\u00e9","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2022.04.004_bib36","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1161\/ATVBAHA.116.308271","article-title":"Estimating the population impact of lp(a) lowering on the incidence of myocardial infarction and aortic stenosis - brief report","volume":"36","author":"Afshar","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.04.004_bib37","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2022.04.004_bib38","first-page":"1953","article-title":"Lipoprotein(a) and cardiovascular and valvular diseases: a genetic epidemiological perspective","volume":"57","author":"Arsenault","year":"2011","journal-title":"Atherosclerosis"},{"issue":"17","key":"10.1016\/j.atherosclerosis.2022.04.004_bib39","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2022.04.004_bib40","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jacbts.2020.06.012","article-title":"Interaction of autotaxin with lipoprotein(a) in patients with calcific aortic valve stenosis","volume":"5","author":"Bourgeois","year":"2020","journal-title":"JACC Basic. Transl. Sci."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2022.04.004_bib41","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/CIRCULATIONAHA.115.016757","article-title":"Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve","volume":"132","author":"Bouchareb","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.04.004_bib42","article-title":"Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis","author":"Kaiser","year":"2021","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.04.004_bib43","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/01.ATV.20.4.1137","article-title":"Major reduction in plasma Lp(a) levels during sepsis and burns","volume":"20","author":"Mooser","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.04.004_bib44","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/bjs.5273","article-title":"Lipoprotein(a), lipids and proinflammatory cytokines in patients undergoing major abdominal surgery","volume":"93","author":"Chimienti","year":"2006","journal-title":"Br. J. Surg."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.04.004_bib45","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1536\/jhj.42.563","article-title":"Effect of cardiopulmonary bypass on plasma levels of lipoprotein (a) in hypercholerterolemic patients","volume":"42","author":"G\u00fcvener","year":"2001","journal-title":"Jpn. Heart J."},{"issue":"25","key":"10.1016\/j.atherosclerosis.2022.04.004_bib46","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1161\/01.CIR.0000130844.01174.55","article-title":"Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein","volume":"109","author":"Tsimikas","year":"2004","journal-title":"Circulation"},{"issue":"2\u20133","key":"10.1016\/j.atherosclerosis.2022.04.004_bib47","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0021-9150(89)90218-9","article-title":"Transient changes of serum lipoprotein(a) as an acute phase protein","volume":"78","author":"Maeda","year":"1989","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2022.04.004_bib48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11883-020-00867-3","article-title":"Lipoprotein(a) and its potential association with thrombosis and inflammation in COVID-19: a testable hypothesis","volume":"22","author":"Moriarty","year":"2020","journal-title":"Curr. Atherosclerosis Rep."},{"key":"10.1016\/j.atherosclerosis.2022.04.004_bib49","article-title":"Lipoprotein(a) and SARS-CoV-2 infections: susceptibility to infections, ischemic heart disease and thromboembolic events","author":"Maio","year":"2021","journal-title":"J. Intern. Med."},{"issue":"January","key":"10.1016\/j.atherosclerosis.2022.04.004_bib50","first-page":"43","article-title":"Lipoprotein(a), venous thromboembolism and COVID-19: a pilot study","volume":"341","author":"Nurmohamed","year":"2021","journal-title":"Atherosclerosis"},{"issue":"13","key":"10.1016\/j.atherosclerosis.2022.04.004_bib51","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.04.004_bib52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"April","key":"10.1016\/j.atherosclerosis.2022.04.004_bib53","first-page":"S22","article-title":"A comparative study on serum lipoprotein (a) and lipid profile between rheumatoid arthritis patients and normal subjects","volume":"7","author":"Shiva Govindan","year":"2015","journal-title":"J. Pharm. BioAllied Sci."},{"key":"10.1016\/j.atherosclerosis.2022.04.004_bib54","series-title":"Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation","first-page":"241","volume":"25","author":"Dursunoglu","year":"2005"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.04.004_bib55","first-page":"415","article-title":"Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-\u03b1-inhibitor","volume":"31","author":"Hjeltnes","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.04.004_bib56","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1194\/jlr.P052209","article-title":"IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans","volume":"56","author":"M\u00fcller","year":"2015","journal-title":"J. Lipid Res."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2022.04.004_bib57","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1136\/annrheumdis-2015-207872","article-title":"Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis","volume":"75","author":"Gabay","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.04.004_bib58","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1053\/j.ajkd.2009.06.029","article-title":"Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus","volume":"54","author":"Krane","year":"2009","journal-title":"Am. J. Kidney Dis."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.04.004_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/ki.2009.503","article-title":"Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease","volume":"77","author":"Barreto","year":"2010","journal-title":"Kidney Int."},{"issue":"22","key":"10.1016\/j.atherosclerosis.2022.04.004_bib60","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/eurheartj\/ehaa1050","article-title":"Lipoproteins in chronic kidney disease: from bench to bedside","volume":"42","author":"Speer","year":"2021","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2022.04.004_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0114397","article-title":"Plasma lipoprotein(a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria","volume":"9","author":"Lin","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.04.004_bib62","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1681\/ASN.V111105","article-title":"Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure","volume":"11","author":"Kronenberg","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2022.04.004_bib63","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0022-2275(20)37150-9","article-title":"Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation","volume":"38","author":"Kronenberg","year":"1997","journal-title":"J. Lipid Res."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2022.04.004_bib64","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/sj.ki.5002131","article-title":"In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients","volume":"71","author":"Frischmann","year":"2007","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.04.004_bib65","doi-asserted-by":"crossref","first-page":"19","DOI":"10.17305\/bjbms.2010.2728","article-title":"Lipoprotein (a) as an acute phase reactant in patients on chronic hemodialysis","volume":"10","author":"Top\u00e7u-Shufta","year":"2010","journal-title":"Bosn. J. Basic Med. Sci."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.04.004_bib66","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1046\/j.1523-1755.1999.00422.x","article-title":"Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure","volume":"55","author":"Stenvinkel","year":"1999","journal-title":"Kidney Int."},{"key":"10.1016\/j.atherosclerosis.2022.04.004_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","author":"Ridker","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.04.004_bib68","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1681\/ASN.V1051027","article-title":"The low molecular weight Apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients","volume":"10","author":"Kronenburg","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.04.004_bib69","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1681\/ASN.2004110922","article-title":"High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients","volume":"16","author":"Longenecker","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2022.04.004_bib70","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1161\/ATVBAHA.117.309920","article-title":"Lipoprotein(a) and risk of myocardial infarction and death in chronic kidney disease findings from the CRIC study (Chronic renal insufficiency cohort)","volume":"37","author":"Bajaj","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.04.004_bib71","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.atherosclerosis.2014.01.049","article-title":"Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk","volume":"234","author":"Langsted","year":"2014","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2022.04.004_bib72","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","article-title":"Prevalence of elevated lp(a) mass levels and patient thresholds in 532 359 patients in the United States","volume":"36","author":"Varvel","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2022.04.004_bib73","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jacc.2021.07.016","article-title":"High-sensitivity C-reactive protein modifies the cardiovascular risk of lipoprotein(a): multi-ethnic study of atherosclerosis","volume":"78","author":"Zhang","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2022.04.004_bib74","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jamacardio.2020.2413","article-title":"Effect of C-reactive protein on lipoprotein(a)-associated cardiovascular risk in optimally treated patients with high-risk vascular disease: a prespecified secondary analysis of the accelerate trial","volume":"5","author":"Puri","year":"2020","journal-title":"JAMA Cardiol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.04.004_bib75","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.004_bib76","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(11)61931-4","article-title":"Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies IL6R Genetics Consortium and Emerging Risk Factors Collaboration","volume":"379","author":"Sarwar","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.04.004_bib77","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1073\/pnas.90.4.1369","article-title":"5\u2019 Control regions of the apolipoprotein(a) gene and members of the related plasminogen gene family","volume":"90","author":"Wade","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.04.004_bib78","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1006\/cyto.2002.1044","article-title":"Il-6 and lipoprotein (a) [Lp(a)] concentrations are related only in patients with high apo(a) isoforms in monoclonal gammopathy","volume":"18","author":"Horv\u00e1th","year":"2002","journal-title":"Cytokine"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2022.04.004_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024719","article-title":"Association between the interleukin-6 promoter polymorphism -174G\/C and serum lipoprotein(a) concentrations in humans","volume":"6","author":"Berthold","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2022.04.004_bib80","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ijcard.2018.06.093","article-title":"Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction","volume":"274","author":"Ueland","year":"2019","journal-title":"Int. J. Cardiol."},{"issue":"30","key":"10.1016\/j.atherosclerosis.2022.04.004_bib81","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","article-title":"Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"37","author":"Kleveland","year":"2016","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.04.004_bib82","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","article-title":"Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study","volume":"74","author":"McInnes","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.04.004_bib83","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jacl.2017.02.018","article-title":"Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: results from the CARdiovascular in rheuMAtology study project","volume":"11","author":"Garc\u00eda-G\u00f3mez","year":"2017","journal-title":"J. Clin. Lipidol."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2022.04.004_bib84","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.04.004_bib85","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jacl.2017.12.004","article-title":"Interleukin-1 genotypes modulate the long-term effect of lipoprotein(a) on cardiovascular events: the Ioannina Study","volume":"12","author":"Naka","year":"2018","journal-title":"J. Clin. Lipidol."},{"issue":"17","key":"10.1016\/j.atherosclerosis.2022.04.004_bib86","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.jacc.2013.12.030","article-title":"Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a)","volume":"63","author":"Tsimikas","year":"2014","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022001812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022001812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:49:38Z","timestamp":1758156578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915022001812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":86,"alternative-id":["S0021915022001812"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.004","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a): An underestimated inflammatory mastermind","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}